Search
Sitagliptin
go.drugbank.com/drugs/DB01261ApprovedInvestigationalSitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesDarunavir
go.drugbank.com/drugs/DB01264ApprovedInvestigationalDarunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to...
Categories: P-glycoprotein inducers, P-glycoprotein inhibitorsLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnLumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Aust...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesOxtriphylline
go.drugbank.com/drugs/DB01303ApprovedOxtriphylline is the choline salt form of theophylline. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesAmobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitA barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmac...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersHexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesRasagiline
go.drugbank.com/drugs/DB01367ApprovedInvestigationalRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesCortisone acetate
go.drugbank.com/drugs/DB01380ApprovedInvestigationalCortisone acetate was first isolate in 1935 and became more widely researched in 1949. Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collag...
Categories: P-glycoprotein inducers, P-glycoprotein substratesBezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalAntilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Synonyms: 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acidCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsColchicine
go.drugbank.com/drugs/DB01394ApprovedInvestigationalColchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Fam...
Categories: P-glycoprotein inducers, P-glycoprotein substrates